Quest Partners LLC Takes $29,000 Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Quest Partners LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 2,110 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at about $123,000. State Board of Administration of Florida Retirement System bought a new position in shares of Stoke Therapeutics in the first quarter worth about $141,000. BNP Paribas Financial Markets lifted its position in shares of Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after purchasing an additional 6,636 shares in the last quarter. Finally, Chase Investment Counsel Corp bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $279,000.

Wall Street Analyst Weigh In

Several research analysts have issued reports on STOK shares. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the sale, the insider now owns 2,485 shares in the company, valued at approximately $34,168.75. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 11.30% of the company’s stock.

Stoke Therapeutics Trading Down 9.2 %

NASDAQ:STOK opened at $13.75 on Friday. The firm has a market capitalization of $723.94 million, a price-to-earnings ratio of -5.71 and a beta of 0.96. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.58. The business’s 50-day moving average price is $14.50 and its two-hundred day moving average price is $13.13.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.